Emerald Investment Advisers LLC Increases Stake in Amgen Inc. $AMGN

Emerald Investment Advisers LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 32.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,256 shares of the medical research company’s stock after purchasing an additional 3,735 shares during the quarter. Emerald Investment Advisers LLC’s holdings in Amgen were worth $5,525,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Roman Butler Fullerton & Co. lifted its stake in shares of Amgen by 1.4% in the second quarter. Roman Butler Fullerton & Co. now owns 1,956 shares of the medical research company’s stock worth $705,000 after buying an additional 27 shares in the last quarter. High Note Wealth LLC grew its stake in Amgen by 5.8% during the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock valued at $166,000 after acquiring an additional 28 shares in the last quarter. TAGStone Capital Inc. grew its stake in Amgen by 0.7% during the 4th quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock valued at $1,351,000 after acquiring an additional 28 shares in the last quarter. Verus Capital Partners LLC raised its holdings in Amgen by 2.3% in the 4th quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock valued at $403,000 after acquiring an additional 28 shares during the last quarter. Finally, Destination Wealth Management raised its holdings in Amgen by 2.1% in the 4th quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock valued at $456,000 after acquiring an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Solid operating performance and dividend support the valuation. Amgen’s second-quarter results exceeded expectations, with revenue rising year over year and earnings per share topping consensus. Continued growth and the company’s dividend are helping support investor confidence. Amgen stock holds close to record high as Q2 2026 growth and dividend support valuation
• Positive Sentiment: Analysts raised their outlook. Argus increased its price target to $460 from $375 while maintaining a Buy rating, citing the latest quarterly performance and progress across Amgen’s drug portfolio. Separate reports also highlighted favorable forecasts from Mizuho and Cantor Fitzgerald, reinforcing the bullish analyst sentiment. Amgen gets a fresh target
• Positive Sentiment: Tarlatamab development advanced. Amgen’s Phase 3 DeLLphi-315 study is evaluating a subcutaneous injection of tarlatamab against the current intravenous infusion approach in lung cancer. A successful shot formulation could improve convenience and broaden the commercial potential of the drug. Amgen advances tarlatamab shot versus infusion in Phase 3 lung cancer study
• Positive Sentiment: Trading momentum and options activity were unusually strong. Amgen was identified as a momentum stock after a substantial recent share-price rally, while call-option volume surged well above typical levels, suggesting increased bullish positioning.
• Neutral Sentiment: Valuation is becoming a consideration. With the stock near its recent high and analysts raising targets, some commentary questioned whether much of the favorable news is already reflected in the share price, which could limit near-term upside.

Amgen Stock Performance

Shares of AMGN stock opened at $439.33 on Friday. The firm’s 50 day moving average price is $379.03 and its 200-day moving average price is $361.95. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. Amgen Inc. has a one year low of $269.77 and a one year high of $443.20. The firm has a market cap of $237.51 billion, a P/E ratio of 27.30, a P/E/G ratio of 3.13 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter last year, the firm earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities research analysts predict that Amgen Inc. will post 22.92 EPS for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Friday, August 21st. Amgen’s dividend payout ratio (DPR) is currently 62.65%.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. This trade represents a 28.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 6,222 shares of company stock valued at $2,540,926 over the last ninety days. Insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on AMGN shares. UBS Group boosted their target price on Amgen from $420.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Freedom Capital upgraded Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Bank of America boosted their price objective on Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. Scotiabank upped their target price on Amgen from $385.00 to $450.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Finally, Cantor Fitzgerald raised their target price on Amgen from $350.00 to $400.00 and gave the stock a “neutral” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $380.43.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.